Frontier Resources (AIM:FRI), agreed to acquire Concepta Diagnostics Limited (“Concepta”), a pioneering UK healthcare company established in 2013, that has developed proprietary products and a platform, which targets the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility. SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Securities as Broker.

This acquisition has been completed, FRI is now CPT

Concepta's flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

One of the directors on this stock is buying and there is news that an order is in from China? Any views on whether this is a stock worth a closer look at ... seems to have gone quiet over the last year or so?

Slow progress, but progress nevertheless. :-

http://www.moneyam.com/action/nav/news?epic=CPT